| Overview |
| bs-70071R |
| Dopamine Transporter (Thr53) Antibody |
| WB |
| Specific for endogenous levels of the ~55 kDa glycosylated form of the DAT protein phosphorylated at Thr53. Relative mobility may vary depending on the state of glycosylation of the DAT protein. The antibody works best in lysates that have not been boiled prior to being run on an SDS-PAGE gel. Immunolabeling is blocked by preadsorption with the phosphopeptide used as antigen, but not by the corresponding non-phosphopeptide. |
| Mouse, Rat |
| Specifications |
| Unconjugated |
| Rabbit |
| Synthetic phospho-peptide corresponding to amino acid residues surrounding Thr53 of rat dopamine transporter, conjugated to keyhole limpet hemocyanin (KLH). |
| Thr53 |
| Polyclonal |
| IgG |
| Lot Dependent |
| Antigen Affinity purification from Pooled whole antiserum |
| 10 mM HEPES (pH 7.5), 150 mM NaCl, 100 µg per ml BSA and 50% glycerol. |
| Storage at -20°C is recommended, as aliquots may be taken without freeze/thawing due to presence of 50% glycerol. Stable for at least 1 year at -20°C. |
| Target |
| 24898 |
| P23977 |
| DA transporter antibody, DAT 1 antibody, DAT antibody, DAT1 antibody, Dopamine transporter 1 antibody, Dopamine transporter antibody, PKDYS antibody, SC6A3_HUMAN antibody, SLC6A3 antibody, Sodium dependent dopamine transporter antibody, Sodium-dependent dopamine transporter antibody, Solute carrier family 6 (neurotransmitter transporter dopamine) member 3 antibody, Solute carrier family 6 (neurotransmitter transporter) member 3 antibody, Solute carrier family 6 member 3 antibody, Variable number tandem repeat (VNTR) antibody |
| The dopamine transporter (DAT) is responsible for the reaccumulation of dopamine after it has been released. DAT antibodies and antibodies for other markers of catecholamine biosynthesis are widely used as markers for dopaminergic and noradrenergic neurons in a variety of applications including depression, schizophrenia, Parkinson’s disease and drug abuse (Kish et al., 2001; Zhu et al., 2000; Zhu et al., 1999). Levels of DAT protein expression are altered by chronic drug administration (Wilson et al., 1996). It has been shown that phosphorylation at Thr-53 directly affects dopamine influx and amphetamine-stimulated substrate efflux, indicating that the Thr-53 residue plays a major role in transport activity (Foster et al., 2012). |
| Application Dilution |
| WB |
1:300-5000 |
Powered by Bioz